About this trial
This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.
Eligibility criteria
Qualifiers
age 18-75 years (due to higher likelihood of undiagnosed cardiac disease or renal insufficiency in patients >75 years of age)
ability to give informed consent
native major papillary anatomy
ability and willingness to obtain bloodwork the day after ERCP
Disqualifiers
prior ERCP with sphincterotomy and/or sphincteroplasty
confirmed or suspected cholangitis or sepsis
confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days
NYHA Class II or greater heart failure
Trial design
Treatments tested in this trial
- Intravenous Ringer's lactate